HC Wainwright & Co. Reiterates Buy on Monopar Therapeutics, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Sean Lee reiterated a Buy rating on Monopar Therapeutics (NASDAQ:MNPR) and maintained a $17 price target.
June 01, 2023 | 5:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Sean Lee reiterated a Buy rating on Monopar Therapeutics and maintained a $17 price target.
The news of HC Wainwright & Co. analyst Sean Lee reiterating a Buy rating on Monopar Therapeutics and maintaining a $17 price target is positive for the stock. This reaffirms the analyst's confidence in the company's potential and could lead to increased investor interest, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100